Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

Stock Information for Zura Bio Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zura Bio Limited

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Announces Chief Financial Officer Transition
Zura Bio to Present at the Jefferies Global Healthcare Conference
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.